在组织发炎、损伤或癌症存在的情况下，多种细胞通过骨髓生成、趋化、细胞迁移和渗出等多步过程被招募到疾病区域。作为新兴的药物传递方法，细胞介导的药物传递利用细胞招募过程来增强治疗性药物到疾病区域的主动运输。在过去的几十年中，出现了各种纳米工程方法，以增强纳米粒子与感兴趣的细胞之间的相互作用，这些方法可以被用于细胞介导的药物传递。此外，药物传递领域可以从细胞基础治疗的最近临床成功中受益，这些方法创建了将循环白细胞改造成“生物活的药物传递载体”来靶向疾病组织的细胞工程方法。在本综述中，我们首先概述了髓系细胞的招募，并讨论了该过程中各种因素如何影响细胞介导的传递。在本综述文章的第二部分中，我们总结了纳米工程和细胞工程方法的现状，并讨论了这些工程方法如何适应细胞介导的传递。最后，我们讨论了这个领域的未来方向，指出细胞介导的药物运输在临床转化中面临的关键挑战。版权所有©2023。由Elsevier B.V.出版。

In the presence of tissue inflammation, injury, or cancer, myeloid cells are recruited to disease regions through a multi-step process involving myelopoiesis, chemotaxis, cell migration, and diapedesis. As an emerging drug delivery approach, cell-mediated drug delivery takes advantage of the cell recruitment process to enhance the active transport of therapeutic cargo to disease regions. In the past few decades, a variety of nano-engineering methods have emerged to enhance interactions of nanoparticles with cells of interest, which can be adapted for cell-mediated drug delivery. Moreover, the drug delivery field can benefit from the recent clinical success of cell-based therapies, which created cell-engineering methods to engineer circulating leukocytes as 'living drug delivery vehicles' to target diseased tissues. In this review, we first provide an overview of myeloid cell recruitment and discuss how various factors within this process may affect cell-mediated delivery. In the second part of this review article, we summarize the status quo of nano-engineering and cell-engineering approaches and discuss how these engineering approaches can be adapted for cell-mediated delivery. Finally, we discuss future directions of this field, pointing out key challenges in the clinical translation of cell-mediated drug delivery.Copyright © 2023. Published by Elsevier B.V.